

REMARKS

In the Office Action, the Examiner has required Applicants to elect a single invention among Groups (I) – (XV) to which the claims must be restricted.

Applicants hereby elect, without traverse, Group (I), claims 1-42, 50-53 and 95-103, drawn to compounds of formula (I), where A is pyrazolo[3,4-d]pyrimidines and simple compositions thereof.

In response to the species election requirements set forth on page 3 of the Office Action, Applicants hereby elect the compound of Example 1 which is a compound of formula I, wherein R1 is methyl, n=0 (R2 is not present), Y is -C(=O)NH-, R3 is cyclopropyl, X1 is a single bond, A is pyrazolo(3,4-d)pyrimidin-1-yl, X2 is a single bond and A is (unsubstituted) phenyl.


It is understood that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim.

Applicants request rejoinder of the method claims of commensurate scope to the composition of matter claims upon allowance of claims directed to the elected invention, e.g., Applicants respectfully request rejoinder of the subject matter corresponding to Groups (V)-(XV) upon allowance of the claims embodying the elected invention.

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
400 Technology Square
Cambridge, MA 02139
(617) 871-3027



Mei L. Benni
Attorney for Applicants
Reg. No. 45,470

Date: *March 25, 2008*